![Pascal Deschaseaux](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Pascal Deschaseaux was the founder and was the Chairman & Chief Executive Officer of Pharmaxon SAS from 2004 to 2012.
He also held former positions as a Principal at Johnson & Johnson and Merck KGaA, and as a Gérant at Pierre Fabre Médicament SAS.
Former positions of Pascal Deschaseaux
Companies | Position | End |
---|---|---|
Pharmaxon SAS
![]() Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008. | Founder | 2012-12-17 |
MERCK KGAA | Corporate Officer/Principal | - |
JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Pierre Fabre Médicament SAS
![]() Pierre Fabre Médicament SAS Pharmaceuticals: OtherHealth Technology Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
MERCK KGAA | Health Technology |
Private companies | 2 |
---|---|
Pharmaxon SAS
![]() Pharmaxon SAS Pharmaceuticals: MajorHealth Technology Despite recent advances in diagnostics, imaging, medical devices and surgical procedures, there has been limited progress in pharmacological treatments for a number of neurological and neuro-oncological pathologies. For pathologies like central and peripheral nervous system injuries, degenerative diseases and tumours of the nervous system, the unmet medical needs are countless and there is growing expectation from the medical community, the patients and their relatives to benefit from clinically proven solutions in the future that will save and/or improve the lives of many. The limited efficacy of approved therapies for some of these pathologies and the orphan nature of others has prompted the urgent need for new researches and therapeutic strategies. At Pharmaxon, as the pioneers of a novel pharmacological approach based on cell mobility modulation, the firm is developing the future 'control keys' for improving the nervous system's endogenous regeneration, modulating neuronal networks plasticity, and inhibiting the processes which underlie tumour cell proliferation and migration. This is obtained by modulating the activity of specific adhesion molecules implicated in cell migration, cell adhesion and cell growth. Based on such a targeted strategy, Pharmaxon is opening up new avenues for the medical management of some serious, poorly-treated, neurology and neuro-oncology pathologies. To date, this has led to three R&D programs which have reached proof-of-principle, confirming the therapeutic potential of this innovative approach, in clinic stage by 2008. | Health Technology |
Pierre Fabre Médicament SAS
![]() Pierre Fabre Médicament SAS Pharmaceuticals: OtherHealth Technology Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France. | Health Technology |
- Stock Market
- Insiders
- Pascal Deschaseaux